Superior magnitude and durability of hybrid immunity following SARS-CoV-2 infection
Asian Pacific Journal of Allergy and Immunology · 2026
DOI: 10.12932/ap-080126-2208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2026. Verfasst von Paskorn Sritipsukho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
Abstract (Originalsprache)
BACKGROUND: The emergence of the SARS-CoV-2 Delta variant necessitated examining hybrid immunity (vaccination- plus-infection) to optimize boosting strategies. We analyzed the kinetics, magnitude, and durability of anti-spike receptor binding domain immunoglobulin G (Anti-sRBD IgG) following Delta infection. OBJECTIVE: This study analyzed the kinetics, magnitude, and long-term durability of anti-spike receptor binding domain immunoglobulin G (Anti-sRBD IgG) levels following Delta variant infection across individuals with diverse vaccination histories. METHODS: This observational cohort study monitored 161 patients with varying vaccination histories for up to 16 weeks post-infection. Responses were compared against SARS-CoV-2 naïve controls receiving a two-dose inactivated series plus a heterologous booster. Sub-analyses assessed post-infection booster immunogenicity. RESULTS: Prior vaccination significantly enhanced humoral responses. Patients with two prior doses achieved the highest median Anti-sRBD IgG peaks, surpassing vaccine-boosted naïve controls. While unvaccinated individuals exhibited delayed primary responses, hybrid immunity demonstrated superior durability with slower antibody decay than vaccine-only immunity. Crucially, while a post-infection booster effectively primed unvaccinated patients, early boosting in previously vaccinated individuals yielded minimal immunological gain. CONCLUSIONS: Prior vaccination significantly enhanced humoral responses. Patients with two prior doses achieved the highest median Anti-sRBD IgG peaks, surpassing vaccine-boosted naïve controls. While unvaccinated individuals exhibited delayed primary responses, hybrid immunity demonstrated superior durability with slower antibody decay than vaccine-only immunity. Crucially, while a post-infection booster effectively primed unvaccinated patients, early boosting in previously vaccinated individuals yielded minimal immunological gain.
Autor:innen und Institutionen
- Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
- Center of Excellence in Applied Epidemiology, Thammasat University, Pathum Thani, Thailand.
- Department of Nucleic Acid Biochemistry, Medical University of Lodz, Lodz, Poland.
- Infectious and Immunology Research Group, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand.
- National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand.
Zitieren
APA
Sritipsukho, P., Nanthapisal, S., Sirichongkolthong, B., Sinlapamongkolkul, P., Jaru-Ampornpan, P., Himananto, O., Yoohat, K., Narkpuk, J., & Deangphare, T. (2026). Superior magnitude and durability of hybrid immunity following SARS-CoV-2 infection. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-080126-2208
Vancouver
Sritipsukho P, Nanthapisal S, Sirichongkolthong B, Sinlapamongkolkul P, Jaru-Ampornpan P, Himananto O, et al. Superior magnitude and durability of hybrid immunity following SARS-CoV-2 infection. Asian Pacific Journal of Allergy and Immunology. 2026. doi:10.12932/ap-080126-2208
BibTeX
@article{Sritipsukho2026,
author = {Sritipsukho, Paskorn and Nanthapisal, Sira and Sirichongkolthong, Boonchu and Sinlapamongkolkul, Pakatip and Jaru-Ampornpan, Peera and Himananto, Orawan and Yoohat, Kirana and Narkpuk, Jaraspim and Deangphare, Thorntun},
title = {Superior magnitude and durability of hybrid immunity following SARS-CoV-2 infection},
journal = {Asian Pacific Journal of Allergy and Immunology},
year = {2026},
doi = {10.12932/ap-080126-2208}
}
EUVIMED